Welcome to our dedicated page for Biote news (Ticker: BTMD), a resource for investors and traders seeking the latest updates and insights on Biote stock.
Biote Corp. reports developments tied to its hormone optimization and healthy aging business, which supports Biote-certified medical providers through training, practice development, operational services and personalized hormone therapy programs. Company updates commonly cover procedure revenue, dietary supplement sales, new provider and clinic growth, commercial team expansion and technology or sales investments aimed at the practitioner network.
Biote news also includes quarterly financial results, outlook commentary, share repurchases, organizational changes and product-supply matters. Its operating updates distinguish procedure-based revenue from Biote-branded dietary supplements and have included disclosures related to Asteria Health, the company’s wholly owned 503B manufacturing subsidiary.
Biote reported strong Q2 2022 financial results, with revenue of $41.4 million, a 19% increase year-over-year, and net income of $49.7 million, a 409% year-over-year rise, primarily due to transaction-related items. Adjusted EBITDA grew 21% to $13.1 million. The company maintains its 2022 revenue guidance of $160-166 million and raises adjusted EBITDA guidance to $47-51 million. Biote is expanding its sales force and exploring markets outside its core geography while focusing on clinical research to enhance its offerings.
biote Corp. (Nasdaq: BTMD) will release its Q2 2022 financial results on August 9, 2022, after market close. A conference call is scheduled for 8:30 a.m. ET on August 10, 2022, where CEO Terry Weber will discuss these results and provide a business update. Biote, a leader in hormone optimization, went public on May 27, 2022. The company offers a range of support to certified practitioners, enhancing hormone therapy through education and software solutions.
Biote Corp. (Nasdaq: BTMD) has appointed Dr. Ross W. McQuivey as Chief Medical Officer, effective June 10, 2022. Dr. McQuivey brings over 20 years of experience in medical leadership, having previously served as CMO at Laborie Medical Technologies. His role will focus on driving clinical research and expanding the Biote Method in mainstream medicine. CEO Terry Weber expressed confidence in Dr. McQuivey’s experience, highlighting its alignment with Biote’s strategic growth plans in the hormone optimization sector.
Biote Corp. (Nasdaq: BTMD) announces a presentation by CEO Terry Weber at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 1:30 p.m. ET, in New York City. The event will be webcasted live with a replay available for 90 days. In addition, Weber and Chairman Marc Beer will engage in investor meetings during the conference. Biote focuses on hormone optimization, training practitioners to detect and address hormone-related aging conditions. The company went public on Nasdaq on May 27, 2022.
Summary not available.
Biote Corp., a medical practice-building company specializing in hormone optimization, has completed its business combination with Haymaker Acquisition Corp. III. This transaction, approved on May 24, 2022, allows Biote to enhance its growth and solidify its market position, with shares trading under the ticker BTMD starting May 27, 2022. The company aims to transform hormone optimization through a robust support network for practitioners and expects to report strong Q2 results in August.